AstraZeneca’s persistence pays off with Imjudo approval
Bio Pharma Dive
OCTOBER 24, 2022
After failing multiple studies, the company’s immunotherapy tremelimumab is cleared to treat liver cancer as part of a regimen that could challenge a similar drug combination from Bristol Myers Squibb.
Let's personalize your content